Latest news

We are pleased to announce our successful DCP submission for Mirabegron prolonged release tablets.  This product has been developed in collaboration with one of our strategic partners, based on the reference brand, Betmiga prolonged release...

Adalvo is pleased to announce a new collaboration with Stendhal, a Mexican pharmaceutical company that provides innovative therapies to improve the quality of life of patients, with presence in Mexico...

In our pursuit of being at the forefront of innovation, we are delighted to share the news of our second successful DCP closure for Desmopressin. While the demand has been...

Adalvo and SteinCares are pleased to announce the extension of their long-term strategic collaboration in Latin America. The companies have recently signed a basket deal for five products to be...

Adalvo is delighted to announce the successful DCP submission of our Dydrogesterone 10mg tablets. Adalvo takes great pride in being amongst the first wave of filers in the EU, with...

We are pleased to announce the successfulDCP approval for Eribulin solution for injection, 0.44mg/ml. As of today, there are no generic MA’s granted for this product. We will now progress with...

Adalvo is excited to announce that we have successfully completed our Pivotal BE program for Azelastine Hydrochloride/ Fluticasone Propionate 137 microgram/50 microgram Nasal Spray.

Adalvo and EQL Pharma have established a formidable partnership, entering into a strategic licensing agreement for Mellozzan® (with active ingredient melatonin). This collaboration grants Adalvo exclusive rights to register, commercialize,...

Adalvo is excited to announce the launch of Solifenacin + Tamsulosin in Europe. Our niche product is a fully bioequivalent version of Vesomni MR Tablets, 6mg/0.4mg, indicated in the treatment...

Adalvo is pleased to announce the successful DCP Submission for Drospirenone + Ethinylestradiol. Drospirenone + Ethinylestradiol has been developed, in collaboration with one of our strategic partners, based on the...

Reference is made to the recent decision by the Federal Patent Court, where the Betmiga (Mirabegron) ’427 patent and its SPC, was declared invalid with effect, for Germany. This decision...

Adalvo is excited to announce our expansion within the US market through a new strategic distribution and collaboration agreement with Sandoz.

Adalvo is thrilled to announce that we have successfully completed our Pivotal BE program for Empagliflozin 25mg film-coated tablets. This product has been developed in collaboration with one of our...

Adalvo is pleased to announce the successful Pivotal BE Study for Riociguat 2.5mg Film Coated Tablets. With our clearly defined product pathway, we believe Adalvo will be amongst the first wave of...

Adalvo is pleased to announce the successful EU DCP Submission for Ivermectin 10mg/g topical cream. With our clearly defined product pathway, we believe Adalvo will be amongst the first wave...

We are thrilled to announce the successful completion of the Pivotal BE Study for Semaglutide 1.34mg/ml pre-filled pen, a product developed in collaboration with one of our strategic partners.  This...

Adalvo has achieved another milestone by successfully completing its Pivotal BE program for the 0.15mg/0.02mg strength of its Desogestrel+Ethinylestradiol film-coated tablets, following the recent news of the completion of the...

We are pleased to announce that we have now completed our Pivotal BE program for Desogestrel+Ethinylestradiol film-coated tablets 0.15mg/0.03mg. This product has been developed in collaboration with one of our...

We are pleased to announce that we have now completed our Pivotal BE program for Levonorgestrel+Ethinylestradiol film-coated tablets 0.15mg/0.03mg. This product has been developed in collaboration with one of our strategic partners....

Adalvo is thrilled to announce that we have successfully completed our Pilot BE program for Empagliflozin+Metformin 12.5mg/1000mg film-coated tablets. This product has been developed in collaboration with one of our...

Adalvo is pleased to announce the successful EU dossier submission for Dalbavancin powder. This achievement further strengthens our infectiology product pipeline and positions Adalvo amongst the few players able to...